Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456

WAF1, a potential mediator of p53 tumor suppression

El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607

Role for a bidentate ribonuclease in the initiation step of RNA interference

Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 5,018

A System for Stable Expression of Short Interfering RNAs in Mammalian Cells

Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,295

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765

RNA interference is mediated by 21- and 22-nucleotide RNAsPreprint

Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,354

Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate

Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel, W., & Tuschl, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6877 · Cited by 1,469

Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding

Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K. H., Wang, H. E., Wettstein, D. A., Stray, K. M., Côté, M., Rich, R. L., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00506-2 · Cited by 1,369

MicroRNA targets in Drosophila

Enright, A. J., John, B., Gaul, U., Tuschl, T., Sander, C., & Marks, D. S. (2003) · Genome Biology · doi:10.1186/gb-2003-5-1-r1 · Cited by 3,597

Expression profiling reveals off-target gene regulation by RNAi

Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370

Small silencing RNAs: an expanding universe

Ghildiyal, M., & Zamore, P. D. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2504 · Cited by 2,418

A biochemical framework for RNA silencing in plantsPreprint

Tang, G., Reinhart, B. J., Bartel, D. P., & Zamore, P. D. (2003) · Genes & Development · doi:10.1101/gad.1048103 · Cited by 994

Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting

Borrero, L. J. H., & El‐Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 805

Drugging p53 in cancer: one protein, many targets

Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 771

Progress towards in Vivo Use of siRNAs

Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677

siRNA vs. shRNA: Similarities and differences

Rao, D. D., Vorhies, J. S., Senzer, N. N., & Nemunaitis, J. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.004 · Cited by 702

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517

Identification of tandem duplicate regulatory small RNAs in Pseudomonas aeruginosa involved in iron homeostasis

Wilderman, P. J., Sowa, N. A., FitzGerald, D. J., FitzGerald, P. C., Gottesman, S., Ochsner, U. A., & Vasil, M. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403423101 · Cited by 455

Lipid-based systemic delivery of siRNA

Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 468

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396

Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing

Harborth, J., Elbashir, S. M., Vandenburgh, K., Manninga, H., Scaringe, S. A., Weber, K., & Tuschl, T. (2003) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729003321629638 · Cited by 474

RNA interference: From gene silencing to gene-specific therapeutics

Leung, R. K. M., & Whittaker, P. A. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.03.004 · Cited by 391

Targeting Oncogenic Mutant p53 for Cancer Therapy

Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 345

The canonical Wnt signalling pathway and its APC partner in colon cancer development

Schneikert, J., & Behrens, J. (2006) · Gut · doi:10.1136/gut.2006.093310 · Cited by 302

Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide

Schwarz, D. S., Ding, H., Kennington, L. A., Moore, J. T., Schelter, J. M., Burchard, J., Linsley, P. S., D, N. A. M., Xu, Z., & Zamore, P. D. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020140 · Cited by 274

Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy

Gulino, A. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s23696 · Cited by 264

SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth.

Filleur, S., Courtin, A., Ait‐Si‐Ali, S., Guglielmi, J., Arnold, C., Harel‐Bellan, A., Clézardin, P., & Cabon, F. (2003) · PubMed · Cited by 253

Therapeutic potential of RNA interference against cancer

Takeshita, F., & Ochiya, T. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00234.x · Cited by 238

Towards applications of bioentities@MOFs in biomedicine

Velásquez-Hernández, M. D. J., Linares‐Moreau, M., Astria, E., Carraro, F., Alyami, M., Khashab, N. M., Sumby, C. J., Doonan, C. J., & Falcaro, P. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213651 · Cited by 242

Strand-specific 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity

Chen, P. Y., Weinmann, L., Gaidatzis, D., Pei, Y., Zavolan, M., Tuschl, T., & Meister, G. (2008) · RNA · doi:10.1261/rna.789808 · Cited by 176

Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53

Dayal, S., Sparks, A., Jacob, J., Allende-Vega, N., Lane, D. P., & Saville, M. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805871200 · Cited by 203

Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)

Nieth, C., Priebsch, A., Stege, A., & Lage, H. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00523-4 · Cited by 203

Highly Efficient Gene Silencing Activity of siRNA Embedded in a Nanostructured Gyroid Cubic Lipid Matrix

Leal, C., Bouxsein, N. F., Ewert, K. K., & Safinya, C. R. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1059763 · Cited by 196

Lipid nanoparticle delivery systems for siRNA-based therapeutics

Wan, C. P. L., Allen, T. M., & Cullis, P. R. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0161-z · Cited by 198

Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles

Miller, V. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh208 · Cited by 172

The therapeutic potential of RNA interference

Uprichard, S. L. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.08.004 · Cited by 162

Cationic Liposome–Nucleic Acid Complexes for Gene Delivery and Silencing: Pathways and Mechanisms for Plasmid DNA and siRNA

Ewert, K. K., Zidovska, A., Ahmad, A. K., Bouxsein, N. F., Evans, H. M., McAllister, C. S., Samuel, C. E., & Safinya, C. R. (2010) · Topics in current chemistry · doi:10.1007/128_2010_70 · Cited by 155

Structure and Gene Silencing Activities of Monovalent and Pentavalent Cationic Lipid Vectors Complexed with siRNA

Bouxsein, N. F., McAllister, C. S., Ewert, K. K., Samuel, C. E., & Safinya, C. R. (2007) · Biochemistry · doi:10.1021/bi062138l · Cited by 155

Many commonly used siRNAs risk off-target activity

Snøve, O., & Holen, T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.175 · Cited by 148

A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference

Lombardi, M. S., Jaspers, L., Spronkmans, C., Gellera, C., Taroni, F., Maria, E. D., Donato, S. D., & Kaemmerer, W. F. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.004 · Cited by 124

Metabolic vulnerability of cisplatin‐resistant cancers

Obrist, F., Michels, J., Durand, S., Chery, A., Pol, J. G., Lévesque, S., Joseph, A., Astesana, V., Pietrocola, F., Wu, G. S., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798597 · Cited by 122

Safety assessment of food and feed from biotechnology-derived crops employing RNA-mediated gene regulation to achieve desired traits: A scientific review

Petrick, J. S., Brower‐Toland, B. D., Jackson, A. L., & Kier, L. D. (2013) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2013.03.008 · Cited by 132

Modulation of Gene Expression by Tumor-Derived p53 Mutants

Scian, M. J., Stagliano, K. E., Ellis, M. A., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1568 · Cited by 117

Identification and Allele-Specific Silencing of the Mutant Huntingtin Allele in Huntington's Disease Patient-Derived Fibroblasts

van Bilsen, P. H. J., Jaspers, L., Lombardi, M. S., Odekerken, J. C. E., Burright, E. N., & Kaemmerer, W. F. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.116 · Cited by 114

Therapeutic siRNAs

Sioud, M. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.11.006 · Cited by 112

The aggregation of mutant p53 produces prion-like properties in cancer

Rangel, L. P., da Costa, D. C. F., Vieira, T. C. R. G., & Silva, J. L. (2014) · Prion · doi:10.4161/pri.27776 · Cited by 111

RNA Interference: A Potent Tool for Gene-Specific Therapeutics

Ichim, T. E., Li, M., Qian, H., Popov, I. A., Rycerz, K., Zheng, X., White, D. J., Zhong, R., & Min, W. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00530.x · Cited by 107

RNAi: a potential new class of therapeutic for human genetic disease

Seyhan, A. A. (2011) · Human Genetics · doi:10.1007/s00439-011-0995-8 · Cited by 104

Inhalable siRNA: Potential as a Therapeutic Agent in the Lungs

Durcan, N., Murphy, C., & Cryan, S. (2008) · Molecular Pharmaceutics · doi:10.1021/mp070048k · Cited by 102

Strategies for targeting undruggable targets

Zhang, G., Zhang, J., Gao, Y., Li, Y., & Li, Y. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1969359 · Cited by 104

Preeclampsia Is Associated with Alterations in the p53-Pathway in Villous Trophoblast

Sharp, A. N., Heazell, A. E. P., Baczyk, D., Dunk, C., Lacey, H. A., Jones, C. J. P., Perkins, J., Kingdom, J. C., Baker, P. N., & Crocker, I. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087621 · Cited by 98

PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa

Saha, M. N., Jiang, H., Yang, Y., Reece, D. E., & Chang, H. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1166 · Cited by 99

Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles

Shin, H., Park, S. D., Yim, Y., Kim, J., Choi, C., Won, C., & Min, D. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800065 · Cited by 95

E2F3 Is a Mediator of DNA Damage-Induced Apoptosis

Martinez, L. A., Goluszko, E., Chen, H., Leone, G. W., Post, S. M., Lozano, G., Chen, Z., & Chauchereau, A. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00938-09 · Cited by 87

Pharmaceutical Prospects for RNA Interference

Schiffelers, R. M., Woodle, M. C., & Scaria, P. V. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000012145.49054.6c · Cited by 85

Targeting Therapies for the p53 Protein in Cancer Treatments

Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84

Toward a Gene Therapy for Dominant Disease: Validation of an RNA Interference-Based Mutation-Independent Approach

Kiang, A., Palfi, A., Ader, M., Kenna, P. F., Millington‐Ward, S., Clark, G., Kennan, A., O’Reilly, M., Tam, L. C. S., Aherne, A., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.028 · Cited by 83

An Efficient System for Cap- and Poly(A)-Dependent Translation In Vitro

Svitkin, Y. V., & Sonenberg, N. (2004) · Humana Press eBooks · doi:10.1385/1-59259-750-5:155 · Cited by 80

A new vector, based on the PolII promoter for the U1 snRNA gene, for the expression of siRNAs in mammalian cells

Denti, M. A., Rosa, A., Sthandier, O., Angelis, F. G. D., & Bozzoni, I. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.04.008 · Cited by 76

RNA interference: on the road to an alternate therapeutic strategy!

Dave, R. S., & Pomerantz, R. J. (2003) · Reviews in Medical Virology · doi:10.1002/rmv.407 · Cited by 73

microRNAs and cancer: role in tumorigenesis, patient classification and therapy

Hernando, E. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0029-0 · Cited by 72

Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells

Ichwan, S. J. A., Yamada, S., Sumrejkanchanakij, P., Auerkari, E. I., Eto, K., & Ikeda, M.-A. (2005) · Oncogene · doi:10.1038/sj.onc.1209158 · Cited by 68

p53 Regulation and Function in Renal Cell Carcinoma

Warburton, H. E., Brady, M., Vlatković, N., Linehan, W. M., PARSONS, K. F., & Boyd, M. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0017 · Cited by 63

Silence of the transcripts: RNA interference in medicine

Barik, S. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0690-0 · Cited by 62

Nanogyroids Incorporating Multivalent Lipids: Enhanced Membrane Charge Density and Pore Forming Ability for Gene Silencing

Leal, C., Ewert, K. K., Shirazi, R. S., Bouxsein, N. F., & Safinya, C. R. (2011) · Langmuir · doi:10.1021/la200679x · Cited by 58

Efficient and specific down-regulation of prion protein expression by RNAi

Tilly, G., Chapuis, J., Vilette, D., Laude, H., & Vilotte, J.-L. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00805-2 · Cited by 59

Selective killing of p53‐deficient cancer cells by SP600125

Jèmaà, M., Vitale, I., Kepp, O., Berardinelli, F., Galluzzi, L., Senovilla, L., Mariño, G., Malik, S. A., Rello‐Varona, S., Lissa, D., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200228 · Cited by 60

RNAi: ancient mechanism with a promising future

Geley, S., & Muller, C. R. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.03.040 · Cited by 66

Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling

Ashley, N., & Poulton, J. (2009) · Oncogene · doi:10.1038/onc.2009.242 · Cited by 57

RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells

Jiang, F., Caraway, N. P., Li, R., & Katz, R. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208459 · Cited by 57

Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy

Chen, Y., & Huang, L. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802568505 · Cited by 55

Design of active small interfering RNAs.

Peek, A. S., & Behlke, M. A. (2007) · PubMed · Cited by 51

Cancer therapeutic targeting using mutant–p53-specific siRNAs

Ubby, I., Krueger, C., Rosato, R., Qian, W., Chang, J., & Sabapathy, K. (2019) · Oncogene · doi:10.1038/s41388-018-0652-y · Cited by 50

Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents

Youlyouz‐Marfak, I., Gachard, N., Clorennec, C. L., Najjar, I., Baran‐Marszak, F., Reminieras, L., May, E., Bornkamm, G. W., Fagard, R., & Feuillard, J. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402270 · Cited by 50

The changing face of p53 in head and neck cancer

Partridge, M., Costea, D. E., & Huang, X. (2007) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2007.06.006 · Cited by 50

Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins

Jiang, W.-Q., Zhong, Z.-H., Nguyen, A., Henson, J. D., Toouli, C. D., Braithwaite, A. W., & Reddel, R. R. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200810084 · Cited by 52

High-throughput gene silencing using cell arrays

Vanhecke, D., & Janitz, M. (2004) · Oncogene · doi:10.1038/sj.onc.1208027 · Cited by 48

Functional genomics using high-throughput RNA interference

Vanhecke, D., & Janitz, M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03352-5 · Cited by 47

Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells

Zheng, J., Teng-xiang, M., Cao, J., Sun, X., Chen, J., Li, W., Wen, R.-M., Sun, Y., & Pei, D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.064 · Cited by 46

The ABCC4 gene is a promising target for pancreatic cancer therapy

Zhang, Z., Wang, J., Shen, B., Peng, C., & Zheng, M. (2011) · Gene · doi:10.1016/j.gene.2011.09.029 · Cited by 46

Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells

Beurel, E., Eggelpoël, M.-J. B.-V., Kornprobst, M., Moritz, S., Delelo, R., Paye, F., Housset, C., & Desbois‐Mouthon, C. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.09.026 · Cited by 46

Using RNAi to catch Drosophila genes in a web of interactions: insights into cancer research

Dasgupta, R., & Perrimon, N. (2004) · Oncogene · doi:10.1038/sj.onc.1208028 · Cited by 46

Molecular genetics of head and neck squamous cell carcinoma

Saâda-Bouzid, E., Peyrade, F., & Guigay, J. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000536 · Cited by 45

The role of p73 in hematological malignancies

Pluta, A., Nyman, U., Joseph, B., Robak, T., Zhivotovsky, B., & Smolewski, P. (2006) · Leukemia · doi:10.1038/sj.leu.2404166 · Cited by 45

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis

Duiker, E. W., Meijer, A., van der Bilt, A. R. M., Meersma, G. J., Kooi, N. M., van der Zee, A. G. J., de Vries, E. G. E., & de Jong, S. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.84 · Cited by 44

Selective silencing of a mutant transthyretin allele by small interfering RNAs

Kurosawa, T., Igarashi, S., Nishizawa, M., & Onodera, O. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.142 · Cited by 43

Single domain antibodies for the knockdown of cytosolic and nuclear proteins

Böldicke, T. W. (2017) · Protein Science · doi:10.1002/pro.3154 · Cited by 45

Enhanced Therapeutic Efficacy by Simultaneously Targeting Two Genetic Defects in Tumors

Zhang, H., Wang, H., Zhang, J., Qian, G., Niu, B., Fan, X., Lu, J., Hoffman, A. R., Hu, J., & Ge, S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.236 · Cited by 42

Activation of p53 in Cervical Cancer Cells by Human Papillomavirus E6 RNA Interference Is Transient, but Can Be Sustained by Inhibiting Endogenous Nuclear Export–Dependent p53 Antagonists

Koivusalo, R., Mialon, A., Pitkänen, H., Westermarck, J. K., & Hietanen, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2185 · Cited by 42

RNA silencing in viral infections: insights from poliovirus

Saleh, M., van Rij, R. P., & Andino, R. (2004) · Virus Research · doi:10.1016/j.virusres.2004.01.010 · Cited by 41

Coordination-based self-assembled capsules (SACs) for protein, CRISPR–Cas9, DNA and RNA delivery

Alimi, L. O., Alyami, M., Chand, S., Baslyman, W. S., & Khashab, N. M. (2021) · Chemical Science · doi:10.1039/d0sc05975g · Cited by 39

OptiRNAi, an RNAi design tool

Cui, W., Ning, J., Naik, U. P., & Duncan, M. K. (2003) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2003.09.002 · Cited by 40

Inhibition of galectins in cancer: Biological challenges for their clinical application

Laderach, D. J., & Compagno, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1104625 · Cited by 38

Potential applications of RNA interference technology in the treatment of cancer.

Lage, H. (2005) · Future Oncology · doi:10.1517/14796694.1.1.103 · Cited by 39

Expression of the Long Noncoding RNA DINO in Human Papillomavirus-Positive Cervical Cancer Cells Reactivates the Dormant TP53 Tumor Suppressor through ATM/CHK2 Signaling

Sharma, S. K., & Münger, K. (2020) · mBio · doi:10.1128/mbio.01190-20 · Cited by 34

Development of gene-specific double-stranded RNA drugs

Barik, S. (2004) · Annals of Medicine · doi:10.1080/07853890410018817 · Cited by 35

Coupling of RNAi-Mediated Target Downregulation with Gene Replacement

Kim, D., & Rossi, J. J. (2003) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729003768247619 · Cited by 33

RNA Interference—A Silent but an Efficient Therapeutic Tool

Ramachandran, P. V., & Savarimuthu Ignacimuthu, S. J. (2013) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-013-0098-1 · Cited by 31

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities

Iyer, S. V., Parrales, A., Begani, P., Narkar, A., Adhikari, A. S., Martinez, L. A., & Iwakuma, T. (2015) · Oncotarget · doi:10.18632/oncotarget.6634 · Cited by 31

Inhibition of GM-CSF Receptor Function by Stable RNA Interference in a NOD/SCID Mouse Hematopoietic Stem Cell Transplantation Model

Scherr, M., Battmer, K., Dallmann, I., Ganser, A., & Eder, M. (2003) · Oligonucleotides · doi:10.1089/154545703322617032 · Cited by 31

RNA molecules as anti-cancer agents

Friedrich, I., Shir, A., KLEIN, S., & Levitzki, A. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.04.001 · Cited by 32

RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research

Chang, H. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701063 · Cited by 30

Gene Discovery in Cervical Cancer

Martin, C. M., Kehoe, L., Spillane, C. D., & O’Leary, J. J. (2007) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256249 · Cited by 30

Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines

Jedidi, A., Marty, C., Oligo, C., Jeanson, L., Ribeil, J., Casadevall, N., Galy, A. H. M., Vainchenker, W., & Villeval, J. (2009) · Blood · doi:10.1182/blood-2008-09-176875 · Cited by 28

p53 mutations and resistance to chemotherapy: A stab in the back for p73

Soussi, T. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00081-3 · Cited by 28

Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls

Trochet, D., Prudhon, B., Vassilopoulos, S., & Bitoun, M. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150812115730 · Cited by 30

p73: regulator in cancer and neural development

Irwin, M. S., & Miller, F. D. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401452 · Cited by 27

Gene‐specific mechanisms of p53 transcriptional control and prospects for cancer therapy

Resnick‐Silverman, L., & Manfredi, J. J. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20925 · Cited by 27

In Brief

(2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd1000

Research Highlights

(2002) · Nature reviews. Cancer · doi:10.1038/nrc959

Cancer therapeutic targeting using mutant–p53-specific siRNAs

Ubby, I., Krueger, C., Rosato, R., Qian, W., Chang, J., & Sabapathy, K. (2019) · Oncogene · doi:10.1038/s41388-018-0652-y · Cited by 50

Selective Inhibition of p53 Dominant Negative Mutation by shRNA Resulting in Partial Restoration of p53 Activity

Chen, E. I.-T., Wu, J., Su, W.-H., Wang, T., & Au, L. (2009) · doi:10.6136/jms.2009.29(4).179

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 576